Department of hepatobiliary surgery, Zhongshan Hospital Affiliated to Zhongshan University, Zhongshan People's Hospital, chief physician Zho
Department of hepatobiliary surgery, Zhongshan Hospital Affiliated to Zhongshan University, Zhongshan People's Hospital, chief physician Zhou Zaiping
Sola Fini (sorafenib) is in recent years the Bayer company developed liver targeting drug for the treatment of advanced renal cell carcinoma in early 2005, after the discovery of the anticancer activity is very wide, the FDA has approved the drug for the treatment of advanced hepatocellular carcinoma, randomized controlled study of patients with advanced hepatocellular carcinoma at present a few large hospitals in China are undergoing the drug last year, the International Union against cancer organization recommended Sola Fini as the standard treatment for advanced hepatocellular carcinoma, which is expected to come out so long trapped in the lack of specific treatment for the liver cancer clinicians see some hope.
The original medical research shows two ways to play Sola Fini mainly by targeting angiogenesis inhibition of tumor cell proliferation and tumor suppression pathway of its anti-cancer effect, can prolong the survival of patients, but the effect is not affected by geographical and ethnic.
Fortunately, Sola Finit specifically inhibits tumor cell proliferation and does not damage normal cells, so it is not classified as cytotoxic chemotherapeutic drugs.
At present, the price of Sola Feeney is very expensive, complications are more, but the medical profession is concerned about and expect it to cooperate with the surgical resection of liver cancer and chemotherapy combined treatment.